HERA

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

Retrieved on: 
Monday, April 1, 2024
SIGA Technologies, TPOXX, Infection, HERA, European, Pharmaceutical industry

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian).

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian).
  • Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.
  • “We are excited about the long-term growth opportunities for oral TPOXX and believe this amendment to the Meridian promotion agreement will be instrumental in driving our expansion efforts for TPOXX outside the U.S.,” said Diem Nguyen, Chief Executive Officer.
  • Certain existing contracts under the promotion agreement, including Meridian’s contract with the European Commission’s DG Health Emergency Preparedness and Response Authority (HERA), will remain in effect.

Terran Orbital’s Milani Satellite Delivered to the European Space Agency for Hera Mission

Retrieved on: 
Tuesday, March 19, 2024
Aerospace, Technology, Manufacturing, Satellite, Telecommunications, Nanotechnology, Networks, Defense, Contracts, Engineering, Mobile, Wireless, INAF, European Space Agency, DART, University of Helsinki, Motivation, University, ESA, International, Travel, Hera, Don Quixote, Tyvak, Science, Geology, Spacecraft, Dust, Australian Space Agency, CubeSat, HERA, VTT, Milani, Brno University of Technology, Mission, Multimedia, Asteroid

Tyvak International SRL (“Tyvak International”), a wholly-owned subsidiary of Terran Orbital Corporation (NYSE: LLAP ) and a leading European nano and microsatellite manufacturer based in Torino, Italy, today announced that they have completed the formal delivery of the Hera Milani satellite to the European Space Agency.

Key Points: 
  • Tyvak International SRL (“Tyvak International”), a wholly-owned subsidiary of Terran Orbital Corporation (NYSE: LLAP ) and a leading European nano and microsatellite manufacturer based in Torino, Italy, today announced that they have completed the formal delivery of the Hera Milani satellite to the European Space Agency.
  • View the full release here: https://www.businesswire.com/news/home/20240319935884/en/
    Ian Carnelli, Hera’s Project Manager for the European Space Agency attended the delivery event together with the Italian Space Agency, the Milani development team, and numerous local and international dignitaries.
  • Hera Milani is a nanosatellite funded by Italy and developed by Tyvak International for the European Space Agency, devoted to the visual inspection and dust detection of the Didymos asteroid following DART impact.
  • We are eager to see the spacecraft in action and help us unveil the many mysteries around the Didymos asteroid system.”
    The Italian Space Agency and European Space Agency decided to dedicate the Mission to Prof. Andrea Milani, who passed away in 2018.

Press release - EU pharmaceutical policy: MEPs support comprehensive reform

Retrieved on: 
Wednesday, April 3, 2024
Health, ERA, Environment, Public health, EPP, Patient, Eras, Research, Food safety, S&D, Prescription, AMR, Commission, Parliament, European Medicines Agency, Council, HERA, Atmosphere, Water, Soil, Marketing, ECDC, Rapporteur, Medication, Pharmaceutical industry

MEPs adopted their proposals to revamp EU pharmaceutical legislation, to foster innovation and enhance the security of supply, accessibility and affordability of medicines.Committee on the Environment, Public Health and Food Safety Source : © European Union, 2024 - EP

Key Points: 


MEPs adopted their proposals to revamp EU pharmaceutical legislation, to foster innovation and enhance the security of supply, accessibility and affordability of medicines.Committee on the Environment, Public Health and Food Safety Source : © European Union, 2024 - EP

MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19

Retrieved on: 
Wednesday, January 31, 2024
Long COVID, ICU, COVID-19, Mortality, Standard of care, HERA, Clinical trial, Pulmonary fibrosis, Patient, Safety, Virus, SOC, CT-05, Disease, Infection, Phases of clinical research, WHO, Pharmaceutical industry

A total of 131 COVID-19 patients were treated with Standard of Care (SoC) plus MetrioPharm’s lead compound MP1032 or with placebo.

Key Points: 
  • A total of 131 COVID-19 patients were treated with Standard of Care (SoC) plus MetrioPharm’s lead compound MP1032 or with placebo.
  • Patients treated with MP1032 (n=86) exhibited a lower mortality compared to those receiving placebo + SoC (n=45).
  • Moreover, the efficacy of MP1032 was enhanced when used in combination with anti-viral agents, including, but not limited to, remdesivir.
  • These protocols had been defined with much larger studies in mind,” said MetrioPharm CSO and co-founder Dr. Wolfgang Brysch.

Press release - Belgium Presidency debriefs EP committees on priorities

Retrieved on: 
Sunday, February 4, 2024
Pillar, Walloon, Education, Climate change, Long-Term Capital Management, Australian Space Agency, Treaty, Rape, PFAS, Policy, Ministry of Social Affairs, Blockchain, Digital identity, AMR, Natural gas, White paper, World Trade Organization, Participatory democracy, High Seas, Partnership, Artificiality, GDPR, European Social Fund Plus, Frustration, CSAM, HERA, NASA Exoplanet Archive, Housing, Safety, SME, Science policy, Government, Justice, Public health, Pesticide, Consumer protection, Mental health, European single market, API, Economy, Science, Finance, State, Commission, Violence, Culture, Artificial intelligence, Medicine, Employment, Student, Development, International trade, Woman, Fishery, Annelies Verlinden, Legislation, Digitization, Transport Select Committee, Research, Service provider, Mutagen, French Community of Belgium, Hydrogen, Death, Artificial Intelligence Act, Kool-Aid, Civil liberties, Civil service, Petra De Sutter, Scientific method, Parliament, Gender equality, Economic recovery, Mercury, Horizon, European Higher Education Area, Carcinogen, Illegal drug trade, AI, European Space Agency, Crime, Foreign Affairs, Ministry of home affairs, Creative Europe, European Health Data Space, Investment, Diversity, Work, Public administration, Food safety, Telecommunications, Farmer, Enlargement, Patent, Legal Affairs, Sport, Electricity, Health, Regional development, Conference

Ministers are holding a series of meetings in parliamentary committees to present the priorities of the Belgian Presidency of the Council.Committee on Culture and EducationCommittee on DevelopmentCommittee on Economic and Monetary AffairsCommittee on Employment and Social AffairsCommittee on the Environment, Public Health and Food SafetyCommittee on Women’s Rights and Gender EqualityCommittee on the Internal Market and Consumer ProtectionCommittee on International TradeCommittee on Industry, Research and EnergyCommittee on Legal AffairsCommittee on Civil Liberties, Justice and Home AffairsCommittee on Regional DevelopmentCommittee on Transport and Tourism Source : © European Union, 2024 - EP

Key Points: 


Ministers are holding a series of meetings in parliamentary committees to present the priorities of the Belgian Presidency of the Council.Committee on Culture and EducationCommittee on DevelopmentCommittee on Economic and Monetary AffairsCommittee on Employment and Social AffairsCommittee on the Environment, Public Health and Food SafetyCommittee on Women’s Rights and Gender EqualityCommittee on the Internal Market and Consumer ProtectionCommittee on International TradeCommittee on Industry, Research and EnergyCommittee on Legal AffairsCommittee on Civil Liberties, Justice and Home AffairsCommittee on Regional DevelopmentCommittee on Transport and Tourism Source : © European Union, 2024 - EP

Fosun International Receives "Excellence in Environmental Positive Impact Commendation" at Hong Kong ESG Reporting Awards

Retrieved on: 
Thursday, November 23, 2023
Carbon, Sustainable development, Social, Climate change, N, TCFD, UN, Global Compact, The Bund Finance Center, Certification, HKSAR, BFC, United Nations, ESG, HKEX, Sustainability, Organization, Gold, Government, Commerce, Financial services, Person, HERA, GRI, Fosun International, Environment, National Certificate, LEED, InvestHK, Carbon neutrality, Social responsibility, EarthCheck, Biodiversity, Water, Silver, Life, Sustainable Development Goals, Ecology, Research, The Business Council, Task force, Biophysical environment, Film industry, Renewable energy, Hong Kong, Health, The Hong Kong, Chinese

HONG KONG, Nov. 22, 2023 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) recently received "Excellence in Environmental Positive Impact Commendation" at the Hong Kong ESG Reporting Awards 2023, in recognition of the company's active green management practices and contribution to environmental protection locally and globally.

Key Points: 
  • HONG KONG, Nov. 22, 2023 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) recently received "Excellence in Environmental Positive Impact Commendation" at the Hong Kong ESG Reporting Awards 2023, in recognition of the company's active green management practices and contribution to environmental protection locally and globally.
  • The Hong Kong ESG Reporting Awards (HERA) is a not-for-profit initiative and one of the most prestigious awards for companies in Hong Kong on corporate sustainability.
  • The Hong Kong ESG Reporting Awards (HERA) aims to recognize companies that have performed outstandingly in ESG reporting and corporate sustainability.
  • This year, Fosun International was awarded "Excellence in Environmental Positive Impact Commendation" by the professional institution in the industry, in recognition of the company's active commitment and efforts in ESG, especially in the environmental front, which have been widely recognized and affirmed.

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA

Retrieved on: 
Monday, October 23, 2023
Other Defense, Infectious Diseases, Contracts, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Defense, European Economic Area, Vaccinia, Medication, SIGA Technologies, Cowpox, Health Emergency Preparedness and Response Authority, Mpox, Meridian Medical Technologies, European Medicines Agency, JPA, MHRA, European, HERA, Smallpox, Tecovirimat, EMA, Joint, Gross metropolitan product, Medicines and Healthcare products Regulatory Agency, Health technology, Patient, Vaccine, Nursing, Meridian, EEA, EU

Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).
  • As part of a promotional licensing agreement, Meridian is a global commercialization partner for SIGA Technologies, Inc. (NASDAQ: SIGA), which is the marketing authorization holder and manufacturer of Tecovirimat SIGA.
  • Under the JPA, 13 participating countries from the European Economic Area (EEA) (Contracting Parties) can now efficiently purchase Tecovirimat SIGA, which has been approved by the European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
  • This agreement will result in country-level procurement of oral Tecovirimat SIGA and serve as a template for future procurement opportunities.

GomSpace and ESA sign Contract Change Notice for €1.500.000 for the Juventas CubeSat implementation

Retrieved on: 
Thursday, August 17, 2023
CubeSat, HERA, GomSpace, ESA, CCN, Juventas

STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- Today, GomSpace and ESA have signed a Contract Change Notice (CCN) with a value of € 1.500.000 (approx. SEK 18 million). The Juventas CubeSat mission is led by GomSpace with support from a range of European subcontractors.

Key Points: 
  • STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- Today, GomSpace and ESA have signed a Contract Change Notice (CCN) with a value of € 1.500.000 (approx.
  • The Juventas CubeSat mission is led by GomSpace with support from a range of European subcontractors.
  • The amount for GomSpace in the CCN is provided to perform system level adaptations to increase the mission robustness.
  • The Juventas spacecraft is expected to be delivered end of 2023 for integration and testing together with the mothercraft HERA.

ISPE Releases Report on its Work Supporting the Establishment of the European Health Emergency Preparedness and Response Authority (HERA)

Retrieved on: 
Wednesday, June 7, 2023
Rahila Hadea Cudjoe, NORTH, Essential, Office of Global Regulatory Operations and Policy, ISPE, CMC, API, Medication, AMR, DG, McKinsey & Company, HERA, European Health Management Association, Chemistry, European Commission, Novartis, Patient, Authority, Knowledge, Merck, Digital, Supply, International Society, Internet service provider, Nursing, EU

NORTH BETHESDA, Md., June 6, 2023 /PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) is excited to release a new report summarizing its 2022 work that helped lay the groundwork for the establishment of the European Health Emergency Preparedness and Response Authority (HERA). ISPE worked with McKinsey & Company on two workstreams for the project, commissioned by the European Health and Digital Executive Agency (HaDEA).

Key Points: 
  • NORTH BETHESDA, Md., June 6, 2023 /PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) is excited to release a new report summarizing its 2022 work that helped lay the groundwork for the establishment of the European Health Emergency Preparedness and Response Authority (HERA).
  • ISPE worked with McKinsey & Company on two workstreams for the project, commissioned by the European Health and Digital Executive Agency (HaDEA).
  • HERA was launched as a new European Commission Directorate-General with a mission to prevent, detect, and rapidly respond to health emergencies.
  • The "Report on ISPE Work to Support Establishment of the European Health Emergency Preparedness and Response Authority (HERA)" is available for download as a bundle with the ISPE report "Increasing Domestic Resiliency in the Supply of Essential Active Pharmaceutical Ingredients" published December 2020 at the ISPE website.

EQS-News: Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

Retrieved on: 
Friday, June 2, 2023
Tumor-associated macrophage, Drug development, University, Frontiers, Tams, Doctor of Philosophy, HERA, Radiation, Patient, Immune system, CD40, TME, TNFRSF, CD40L, Tumor microenvironment, Prostate cancer, Pharmaceutical industry, Vaccine, Immunology

In the studies, Apogenix, in collaboration with the group from Professor Tim Illidge at the University of Manchester, UK, demonstrated the therapeutic benefits of the hexavalent CD40 agonist HERA-CD40L in models of prostate cancer refractory to anti-PD-1 therapies, both as monotherapy and in combination with radiotherapy.

Key Points: 
  • In the studies, Apogenix, in collaboration with the group from Professor Tim Illidge at the University of Manchester, UK, demonstrated the therapeutic benefits of the hexavalent CD40 agonist HERA-CD40L in models of prostate cancer refractory to anti-PD-1 therapies, both as monotherapy and in combination with radiotherapy.
  • Thomas Hoeger, PhD, CEO of Apogenix, said: “Immune checkpoint inhibitors have revolutionized cancer treatment, however, the overall response rate for all cancer types in patients is still below twenty percent.
  • HERA-CD40L is a novel molecule from Apogenix’ platform of hexavalent Tumor Necrosis Factor Receptor Superfamily (TNFRSF) agonists.
  • Due to its characteristic of bridging the transition from innate immunity to the initiation of adaptive immunity, CD40 represents a very attractive target for drug development.